Commercial License Terms May Govern Even Without Contracting Officer Knowledge
Client Alert | 1 min read | 07.30.18
On June 27, 2018, in Appeal of CiyaSoft Corporation, the Armed Services Board of Contract Appeals held that the government breached the terms of a commercial software license agreement even though the contracting officer (CO) had not even seen that license. Here CiyaSoft appealed a claim asserting that the Army had breached the terms of its license by using more copies of the software than were permitted. The Army had denied the claim, in part, because the writing between the parties contained no terms specifying how the government would secure and protect the software. However, CiyaSoft had included license terms limiting the software’s use (i) inside the box containing the CDs with the software, (ii) on a piece of paper inside the software’s shrinkwrap, and (iii) in clickwrap that was displayed during the software’s installation process. On appeal, the Board found that although the writing between the parties did not include all of the relevant license terms and the CO never saw or discussed those license terms with CiyaSoft, the CO had a duty to inquire about those license terms and the failure to do so imputed knowledge of the licensing terms on the Army. Highlighting the longstanding policy that the government should accept commercial computer license terms that are customarily provided to other purchasers, the Board held that “the government can be bound by the terms of a commercial software license it has neither negotiated nor seen prior to the receipt of the software, so long as the terms are consistent with those customarily provided by the vendor to other purchasers and do not otherwise violate federal law.”
After finding that the Army could be subject to CiyaSoft’s commercial license terms, the Board then determined that the software was “commercial computer software” under FAR 2.101 because (1) it was developed without government funds, (2) it had been sold to at least one non-governmental entity, and (3) the modifications to the software prior to delivery to the Army did not affect the software’s core purpose.
Contacts
Insights
Client Alert | 7 min read | 09.14.26
AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development
Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage.
Client Alert | 6 min read | 09.14.26
Mental Health Parity Bulletin Restates Best Practices for Evaluating Compliance
Client Alert | 6 min read | 09.11.26
It’s LIVE: The Cyber Resilience Act Reporting Is Mandatory as of Today - 11 September 2026
Client Alert | 10 min read | 09.11.26
Mining, Indigenous Consultation Rights, and Investment Treaty Protection





